COMMUNIQUÉS West-GlobeNewswire

Centre for Neuro Skills CEO David Harrington Joins Brain to Brain Podcast to Discuss the Science of Recovery, Advocacy for Brain Injury Care and Why It Is Never Too Late
30/04/2026
Brain injury rehabilitation leader shares his personal story, CNS’s recovery-focused philosophy and the real barriers patients face in accessing the care they need BAKERSFIELD, Calif., April 30, 2026 (GLOBE NEWSWIRE [...]
Oncotelic Therapeutics Advances Toward Commercial Launch of AI-Enabled Robotics Platform Following Integration of 28 Million Scientific Abstracts
30/04/2026
LOS ANGELES, April 30, 2026 (GLOBE NEWSWIRE) -- via IBN -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB: OTLC), a clinical-stage biotechnology company focused on oncology and AI-driven solutions, [...]
Former Stryker Medical Division President Brad Saar Joins Sonablate Board to Support Growth of Non-Invasive Prostate Cancer Treatment
30/04/2026
Appointment signals next phase of expansion for HIFU-based prostate care as demand grows for non-invasive, function-preserving treatment options CHARLOTTE, N.C., April 30, 2026 (GLOBE NEWSWIRE) -- Sonablate, a medical [...]
VIVUS Announces QSIVA® Price Reduction Across Nordics and Poland
30/04/2026
— The new pricing structure is made available as of February for 12,67 PLN per day at pharmacies throughout Poland AMSTERDAM, April 30, 2026 (GLOBE NEWSWIRE) -- VIVUS BV, a subsidiary of VIVUS LLC, a biopharmaceutical [...]
Glucotrack Announces Publication of Peer-Reviewed Study In The Journal of Diabetes Research Demonstrating Long-Term Accuracy and Stability of Continuous Blood Glucose Monitoring Technology
30/04/2026
In-Vivo Ovine Study Demonstrates Sustained Performance Of Company’s Continuous Blood Glucose Monitoring (CBGM) Technology Over 240 Days, Reinforces Path to Key IDE Submission RUTHERFORD, N.J., April 30, 2026 (GLOBE [...]
LENSAR® to Report First Quarter 2026 Results on May 8, 2026
30/04/2026
ORLANDO, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, [...]
Axogen, Inc. to Participate in the 2026 Bank of America Global Healthcare Conference
30/04/2026
ALACHUA, Fla. and TAMPA, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, [...]
Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
30/04/2026
Q1’26 Total Net Revenue of $317 Million, Up 19% YoY Q1’26 Total SUBLOCADE® Net Revenue of $232 Million, Up 32% YoY Q1'26 GAAP Net Income of $89 Million and Q1'26 Non-GAAP Net Income of $123 Million Record Quarterly [...]
Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility
30/04/2026
At one-year mark, company has progressed all components of US investment plan to support delivery of innovative medicines to US patients New active pharmaceutical ingredients facility in North Carolina to enable end‑to‑ [...]
Vireo Growth to Acquire FLUENT in All-Stock Transaction
30/04/2026
MINNEAPOLIS and TAMPA, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (CSE: VREO) (OTCQX: VREOF) (“Vireo”), a multi-state cannabis operator, and FLUENT Corp. (CSE: FNT.U) (OTCQB: CNTMF) (“FLUENT” or the “ [...]
AC Immune First Quarter 2026 Financial and Corporate Updates
30/04/2026
AC Immune First Quarter 2026 Financial and Corporate Updates Dosed first subjects in Phase 1 trial of brain-penetrant small molecule NLRP3 inhibitor ACI-19764 with SAD/MAD results in healthy volunteers expected in H2 [...]
Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility
30/04/2026
At one-year mark, company has progressed all components of US investment plan to support delivery of innovative medicines to US patients New active pharmaceutical ingredients facility in North Carolina to enable end‑to‑ [...]
BridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ET
30/04/2026
PALO ALTO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today [...]
Option Care Health Announces Financial Results for the First Quarter Ended March 31, 2026
30/04/2026
BANNOCKBURN, Ill., April 30, 2026 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion [...]
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease
30/04/2026
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease Treatment of first patient in Cohort AD4 in ABATE trial triggers $12 million milestone [...]
TG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business Update
30/04/2026
Conference Call to be Held Wednesday, May 6, 2026, at 8:30 am ET NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Wednesday, May 6, [...]
Medicenna and Fondazione Melanoma Onlus Announce Presentation on NEOCYT Trial at ASCO 2026
30/04/2026
NEO-CYT is a randomized, multi-centre trial of neoadjuvant MDNA11 (before curative intent surgery) sponsored by the Fondazione Melanoma Onlus, and led by Professor Paolo A. Ascierto of the Istituto Nazionale Tumori [...]
BioStem Strengthens Leadership Team with Appointment of Katherine Gorrell as Chief Legal & Compliance Officer
30/04/2026
Adds accomplished legal and compliance executive with two decades of experience advising healthcare organizations through complex regulatory, governance, and growth initiatives POMPANO BEACH, Fla., April 30, 2026 (GLOBE [...]
uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington’s Disease
30/04/2026
~ Submission of a UK Marketing Authorization Application for AMT-130 is expected in the third quarter of 2026 ~ ~ Type B Meeting with U.S. FDA granted in second quarter; expect to discuss potential Phase III design and [...]

Pages